Identification (references) | Year of publication | State | Study design | Sample sizea | Target antigenbc | Overall seroprevalence (%) | 95% CI |
---|---|---|---|---|---|---|---|
Rodrigues da Silva et al. [34] | 2016 | Rondônia | Cross-sectional | 545 | PvMSP9-RIRII | 58 | 53.86–62.14 |
PvMSP9-E795/A808 | 32.5 | 28.57–36.43 | |||||
Sanchez-Arcila et al. [30] | 2015 | Rondônia | Cross-sectional | 279 | PvMSP119 | 66 | 60.44–71.56 |
PvAMA-1(Picchia pastoris) | 63 | 57.33–68.67 | |||||
Cunha et al. [28] | 2014 | ParĂ¡ | Cross-sectional | 1330 | PfMSP119 | 25.6 | 23.25–27.95 |
PfAMA-1 | 12.7 | 10.91–14.49 | |||||
PvMSP119 | 36.3 | 33.72–38.88 | |||||
PvAMA-1 | 32.5 | 29.98–35.02 | |||||
Ferreira et al. [38] | 2014 | Rondônia | Cross-sectional | 253 | PvRMC-RBP1 | 47.1 | 40.95–53.25 |
PvRBP1-23-751 | 60 | 53.96–66.04 | |||||
Versiani et al. [41] | 2013 | Amazonas | Cohort | 308 | PvMSP1 (N-terminus) | 35.4 | 30.06–40.74 |
Lima Junior et al. [33] | 2012 | Rondônia | Cross-sectional | 276 | PvMSP119 | 86.7 | 82.69–90.71 |
PvMSP3-alpha | 77 | 72.04–81.96 | |||||
PvMSP9 | 76 | 70.96–81.04 | |||||
Kano et al. [29] | 2012 | Amazonas | Cross-sectional | 432 | PvDBP | 49.5 | 44.79–54.21 |
PvMSP119 | 86.7 | 83.5–89.9 | |||||
Lima Junior et al. [32] | 2011 | Rondônia | Cross-sectional | 282 | PvMSP3-alpha | 78 | 73.17–82.83 |
Souza-Silva et al. [40] | 2010 | Acre | Cohort | 366 | PvDBP | 18.6 | 14.61–22.59 |
Lima Junior et al. [31] | 2008 | Rondônia | Cross-sectional | 306 | PvMSP9 | 74 | 69.1–78.91 |
Ladeia-Andrade et al. [27] | 2007 | Amazonas | Cross-sectional | 812 778 | PvMSP119 | 66.3d | 62.93–69.43 |
PfMSP119 (Saccharomyces cerevisae) | 53.5d | 49.96–56.95 | |||||
Bastos et al. [18] | 2007 | Acre | Cohort | 376 | PvMSP119 | 54.3 | 46.29–59.34 |
Suarez-Mutis et al. [24] | 2007 | Amazonas | Cross-sectional | 98 | PvMSP119 | 46.9 | 37.02–56.78 |
Scopel et al. [25] | 2007 | Acre | Cohort | 356 | PfMSP-2 S20 | 28.1 | 23.43–32.77 |
PfMSP-2 FC27 | 22.2 | 17.88–26.52 | |||||
PfMSP-2 AM89 | 7.3 | 4.6–10 | |||||
PfMSP-2 3D7 | 6.2 | 3.69–8.71 | |||||
PfMSP-2 FUP/CP | 6.2 | 3.69–8.71 | |||||
Nogueira et al. [39] | 2006 | Rondônia | Cohort | 429 | N-terminus–PvMSP1 | 35d | 30.6–39.59 |
PvMSP119 | 41.5d | 36.93–46.21 | |||||
Tran et al. [37] | 2005 | Rondônia | Cross-sectional | 294 | PvDBP | 67 | 61.63–72,37 |
PvRBP-1 | 66 | 60.59–71.47 | |||||
Marcano et al. [15] | 2004 | Roraima | Cross-sectional | 101 | Pf blood stages (IFAT) | 72.1 | 63.35–80.85 |
Alexandre et al. [26] | 1997 | Amazonas | Cross-sectional | 241 | PfR44 | 26.5e | 20.93–32.07 |
PfAg-T | 57.7e | 51.43–63.91 | |||||
Arruda et al. [14] | 1996 | ParĂ¡ | Cross-sectional | 430 | PfCS | 44f | 39.33–48.71 |
Pf blood stage (IFAT) | 68f | 63.54–72.36 | |||||
PvCS | 60.1e | 55.42–64.68 | |||||
Pv blood stage (IFAT) | 73.2e | 68.98–77.36 | |||||
Ferreira et al. [17] | 1994 | Rondônia | Cohort | 50 | Pf Exoantigens | 30g | 17.3–42.7 |
Pf Somatic Antigens | 40g | 26.42–53.58 | |||||
Oliveira-Ferreira et al. [16] | 1992 | Rondônia | Cross-sectional | 1617 | PfCS (Immunoradiometric) | 5.9 | 4.75–7.05 |
Pf Blood stage (IFAT) | 49.2 | 46.76–51.64 | |||||
Kremsner et al. [23] | 1992 | Acre | Cross-sectional | 645 | PvCS | 17.3f | 14.33–20.17 |
PvCS (VK247) | 4.8f | 3.11–6.39 | |||||
Jeffery et al. [19] | 1975 | Mato Grosso | Cross-sectional | 4270 | Pf and Pv blood stage (IFAT) | 10.5h | 9.58–11.42 |